AMETHYST Phase 3 and Remaining Questions Surrounding Litifilimab in CLE

Cutaneous lupus erythematosus (CLE) remains one of dermatology's most consequential unmet needs. Despite its prevalence, chronicity, and capacity for permanent disfigurement, no targeted therapy has ever been approved for the disease, and the clinical trial landscape has historically been sparse. That context makes the emerging litifilimab program not only scientifically significant but unusually anticipated — 2 positive Phase 2 trials in a condition where positive Phase 2 data alone represent a meaningful advance.

With consistent efficacy signals established across the LILAC and AMETHYST Part A studies, attention now turns to AMETHYST Part B, the phase 3 portion of the phase 2/3 trial, which is currently ongoing with results remaining blinded. Part B will be critical in several respects.

It will need to confirm the efficacy signal observed in Part A in a larger, more powered population, establish the durability of response beyond the 24-week controlled period examined in Phase 2, and provide the robust safety dataset that will ultimately inform regulatory review. Importantly, AMETHYST was designed with a globally representative enrollment strategy, with 74% women and 33% non-white participants in Part A, reflecting the demographic realities of CLE. Whether that representation is maintained and whether the efficacy signal holds across subgroups defined by disease subtype, severity, and background therapy will be among the most closely watched questions as Phase 3 data mature.¹

For clinicians who have long managed CLE with tools borrowed from adjacent indications, the prospect of a purpose-built, mechanism-driven therapy with a Phase 3 program underway is a substantive shift in the trajectory of the field. The Breakthrough Therapy Designation granted to litifilimab by the FDA adds further momentum, signaling regulatory recognition of both the unmet need and the strength of the existing evidence base.

In this segment, Joseph Merola, MD, MMSc, and Victoria Werth, MD, share what they are most anticipating from the AMETHYST Phase 3 program, which data points will be most informative for clinical practice, and what approval of a first targeted therapy for CLE would mean for patients who have been waiting decades for a better option.

References

1. Biogen Inc. Biogen announces second positive Phase 2 litifilimab trial in cutaneous lupus erythematosus at 2026 American Academy of Dermatology Annual Meeting, showing a significant reduction in skin disease activity. Published March 28, 2026. https://investors.biogen.com/news-releases/news-release-details/biogen-announces-second-positive-phase-2-litifilimab-trial